Format

Send to

Choose Destination

See 1 citation found by title matching your search:

PLoS One. 2016 Dec 29;11(12):e0169065. doi: 10.1371/journal.pone.0169065. eCollection 2016.

A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy.

Author information

1
University of Groningen, Groningen Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology and -Economics (PTE2), Groningen, the Netherlands.
2
University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, the Netherlands.
3
University Medical Center Groningen (UMCG), Institute for Science in Healthy Aging & HealthcaRE (SHARE), Groningen, the Netherlands.
4
University Medical Center Groningen (UMCG), Department of Epidemiology, Groningen, the Netherlands.

Abstract

OBJECTIVE:

Genotyping for CYP2D6 has the potential to predict differences in metabolism of nortriptyline. This information could optimize pharmacotherapy. We determined the costs and effects of routine genotyping for old aged Dutch depressed inpatients.

METHODS:

With a decision-tree, we modelled the first 12 weeks of nortriptyline therapy. Direct costs of genotyping, hospitalization, therapeutic drug monitoring and drugs were included. Based on genotype, patients could be correctly, sub-, or supratherapeutically dosed. Improvement from sub- or supratherapeutically dosed patients to correctly dosed patients was simulated, assuming that genotyping would prevent under- or overdosing of patients. In the base case, this improvement was assumed to be 35%. A probabilistic sensitivity analysis (PSA) was performed to determine uncertainty around the incremental cost-effectiveness ratio (ICER).

RESULTS:

In the base case analysis, costs for genotyping were assumed €200 per test with a corresponding ICER at €1 333 000 per QALY. To reach a €50 000 per QALY cut-off, genotyping costs should be decreased towards €40 per test. At genotyping test costs < €35 per test, genotyping was dominant. At test costs of €17 per test there was a 95% probability that genotyping was cost-effective at €50 000 per QALY.

CONCLUSIONS:

CYP2D6 genotyping was not cost-effective at current genotyping costs at a €50 000 per QALY threshold, however at test costs below €40, genotyping could be costs-effective.

PMID:
28033366
PMCID:
PMC5199075
DOI:
10.1371/journal.pone.0169065
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Maarten J. Postma has received research grants and fees from several pharmaceutical companies (GSK, Pfizer, SPMSD, Shire, Sanofi, Bayer, BMS, MedImmune, Novimmune, Astra Zeneca, Johnson & Johnson, Boehringer Ingelheim, Mundipharma, Sigma Tau, Novartis, AbbVie, Gilead, Astellas, Eli Lilly, Vertex and MSD) unrelated to the subject matter of this paper. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center